Welcome to Seagull Pharmacy!
Current Location:Home>Medical Information>Dosage of Avirumab (Bavencio)
Dosage of Avirumab (Bavencio)
Publisher:海鸥医学顾问     Publication Date:2025-09-16 17:28      The article comes from the Internet

The dosage of Bavencio varies according to the indications, mainly using a standard regimen of intravenous infusion of 800mg every 2 weeks for 60 minutes, with some cases requiring combination therapy or preoperative management. The following provides a detailed explanation of the recommended dosage and special precautions for each indication.

1. General Medication Guidelines

(1) Preoperative medication: Antihistamines and acetaminophen should be used for pre-treatment before the first 4 infusions, and adjustments should be made based on the infusion response.

(2) Standard dose: For most indications, 800mg/time is administered intravenously every 2 weeks for 60 minutes until disease progression or intolerable toxicity occurs.

2. Indicative specific dosage

(1) Merkel cell carcinoma: Single drug 800mg infused every 2 weeks, no need for combination therapy.

(2) Urethral epithelial cancer: same as Merkel cell carcinoma regimen, maintaining monotherapy mode.

(3) Renal cell carcinoma: Combination with Axitinib 5mg orally twice daily, with Axitinib increasing at discretion.

3 Special precautions

(1) Overdose treatment: There are no clear reports yet, immediate discontinuation of medication and supportive treatment are required.

(2) Dosage characteristics: Use 20mg/mL transparent solution, packaged in single dose small bottles.

Disclaimer:《Dosage of Avirumab (Bavencio)》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication!

Related Drugs

Bavencio

Full Name:

Reference Price:$10800.00

Prescribing Information: 阿维鲁单抗(Bavencio)是由辉瑞与德国默克公司联合研发的PD-L1免疫检查点抑制剂,2017年获FDA批准上市,成为全球首个治疗转移性默克尔细胞癌(MCC)的免疫疗法。 1.药品名称与主要成分‌ 通用名‌: 阿维鲁单抗(Avelumab) 商品名‌: B...